HER-2 positive and p53 negative breast cancers are associated with poor prognosis.

Hdl Handle:
http://hdl.handle.net/10147/136397
Title:
HER-2 positive and p53 negative breast cancers are associated with poor prognosis.
Authors:
Al-azawi, Dhafir; Leong, Sum; Wong, Limy; Kay, Elaine; Hill, Arnold D K; Young, Leonie
Affiliation:
Department of Surgery, Beaumont Hospital, Dublin, Ireland. dalazawi@rcsi.ie
Citation:
HER-2 positive and p53 negative breast cancers are associated with poor prognosis. 2011, 29 (5):365-9 Cancer Invest.
Journal:
Cancer investigation
Issue Date:
Jun-2011
URI:
http://hdl.handle.net/10147/136397
DOI:
10.3109/07357907.2011.584586
PubMed ID:
21599513
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21599513
Abstract:
p53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02) . p53 expression relates to HER-2 expression (p = .029). Coexpression between p53 and HER-2 has no relation to prognosis. On univariate and multivariate analysis, combination of HER-2 positive and p53 negative expression was associated with a poor prognosis (p = .018 and p = .027, respectively), while the combination of HER-2 negative and p53 positive expression was associated with a favorable prognosis (p = .022 and p = .010, respectively). Therefore the expression of these markers should be considered collectively.
Item Type:
Article
Language:
en
ISSN:
1532-4192

Full metadata record

DC FieldValue Language
dc.contributor.authorAl-azawi, Dhafiren
dc.contributor.authorLeong, Sumen
dc.contributor.authorWong, Limyen
dc.contributor.authorKay, Elaineen
dc.contributor.authorHill, Arnold D Ken
dc.contributor.authorYoung, Leonieen
dc.date.accessioned2011-07-20T10:04:48Z-
dc.date.available2011-07-20T10:04:48Z-
dc.date.issued2011-06-
dc.identifier.citationHER-2 positive and p53 negative breast cancers are associated with poor prognosis. 2011, 29 (5):365-9 Cancer Invest.en
dc.identifier.issn1532-4192-
dc.identifier.pmid21599513-
dc.identifier.doi10.3109/07357907.2011.584586-
dc.identifier.urihttp://hdl.handle.net/10147/136397-
dc.description.abstractp53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02) . p53 expression relates to HER-2 expression (p = .029). Coexpression between p53 and HER-2 has no relation to prognosis. On univariate and multivariate analysis, combination of HER-2 positive and p53 negative expression was associated with a poor prognosis (p = .018 and p = .027, respectively), while the combination of HER-2 negative and p53 positive expression was associated with a favorable prognosis (p = .022 and p = .010, respectively). Therefore the expression of these markers should be considered collectively.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21599513en
dc.titleHER-2 positive and p53 negative breast cancers are associated with poor prognosis.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Beaumont Hospital, Dublin, Ireland. dalazawi@rcsi.ieen
dc.identifier.journalCancer investigationen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.